Friday, March 03, 2023 12:48:03 PM
CES and VMX were both a great success and have brought us exciting opportunities that we are currently exploring, as we have stated in previously new releases there is nothing like the GluCurve Pet CGM on the market for veterinarians and the device and software make monitoring and treating diabetes easier for the doctor, pet parent, and pet. We hope to have numerous updates in the coming months but unfortunately, we cannot share anything publicly at this time.
We appreciate your patience and loyalty as an investor and are working hard to try and bring significant value to shareholders in 2023 and beyond.
V/r
Joe Stern
Head of Animal Health
Recent ALRTF News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/29/2023 12:53:49 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/28/2023 08:49:25 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/10/2023 09:15:16 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM